These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 1772327)
1. Compound M & B 39890A [N-(3-imidazol-1-ylpropyl)- 2-(3-trifluoromethylbenezensulphonamido)-benzamide hydrochloride], a glucagon and insulin secretion inhibitor, improves insulin sensitivity in viable yellow obese-diabetic mice. Yen TT; Schmiegel KK; Gold G; Williams GD; Dininger NB; Broderick CL; Gill AM Arch Int Pharmacodyn Ther; 1991; 310():162-74. PubMed ID: 1772327 [TBL] [Abstract][Full Text] [Related]
2. Effect of a hypoglycaemic agent M&B 39890A on glucagon secretion in isolated rat islets of Langerhans. Tadayyon M; Green I; Cook D; Pratt J Diabetologia; 1987 Jan; 30(1):41-3. PubMed ID: 3552819 [TBL] [Abstract][Full Text] [Related]
3. M&B 39890A, a novel sulphonamido-benzamide compound, inhibits insulin and glucagon secretion in vitro. Silvestre RA; Peiró E; Miralles P; Marco J Biochem Pharmacol; 1989 Aug; 38(15):2565-8. PubMed ID: 2569305 [No Abstract] [Full Text] [Related]
4. Insulin and glucagon secretion in streptozotocin-diabetic rats: influences of islets transplanted to the renal subcapsular space. Ar'Rajab A; Ahrén B; Bengmark S Diabetes Res; 1989 Sep; 12(1):37-41. PubMed ID: 2517050 [TBL] [Abstract][Full Text] [Related]
5. Insulin and glucagon releasing activity of coleonol (forskolin) and its effect on blood glucose level in normal and alloxan diabetic rats. Ahmad F; Khan MM; Rastogi AK; Kidwai JR Acta Diabetol Lat; 1991; 28(1):71-7. PubMed ID: 1650516 [TBL] [Abstract][Full Text] [Related]
6. Abnormal insulin secretion in a streptozocin model of diabetes. Effects of insulin treatment. Leahy JL; Bonner-Weir S; Weir GC Diabetes; 1985 Jul; 34(7):660-6. PubMed ID: 2408948 [TBL] [Abstract][Full Text] [Related]
7. Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist. Strowski MZ; Cashen DE; Birzin ET; Yang L; Singh V; Jacks TM; Nowak KW; Rohrer SP; Patchett AA; Smith RG; Schaeffer JM Endocrinology; 2006 Oct; 147(10):4664-73. PubMed ID: 16857751 [TBL] [Abstract][Full Text] [Related]
8. (-)-BM 13.0913: a new oral antidiabetic agent that improves insulin sensitivity in animal models of type II (non-insulin-dependent) diabetes mellitus. Freund P; Wolff HP; Kühnle HF Metabolism; 1995 May; 44(5):570-6. PubMed ID: 7752903 [TBL] [Abstract][Full Text] [Related]
9. Restoration of the A cell response to glucose in isolated rat islets of Langerhans. Hii CS; Howell SL Mol Cell Endocrinol; 1986 Dec; 48(2-3):199-204. PubMed ID: 3542631 [TBL] [Abstract][Full Text] [Related]
10. Modulation of gliquidone action by forskolin in the pancreas of normal and GK rats. Leclercq-Meyer V; Malaisse WJ Am J Physiol; 1997 Jul; 273(1 Pt 1):E52-8. PubMed ID: 9252479 [TBL] [Abstract][Full Text] [Related]
11. Islet transplantation to the renal subcapsular space in streptozotocin-diabetic rats. Long-term effects on insulin and glucagon secretion. Ar'Rajab A; Ahrén B; Alumets J; Bengmark S Acta Chir Scand; 1989 Oct; 155(10):503-8. PubMed ID: 2513696 [TBL] [Abstract][Full Text] [Related]
12. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice. O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054 [TBL] [Abstract][Full Text] [Related]
13. Effect of tolbutamide on insulin, glucagon, and somatostatin release from the diabetic rat pancreas with special reference to glucose concentration. Kadowaki S; Taminato T; Chiba T; Nozawa M; Fujita T; Norman AW Endocrinology; 1983 Jun; 112(6):2187-92. PubMed ID: 6133743 [TBL] [Abstract][Full Text] [Related]
14. MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice. Bhattacharjee A; Allister EM; Wheeler MB Can J Physiol Pharmacol; 2012 May; 90(5):663-8. PubMed ID: 22530993 [TBL] [Abstract][Full Text] [Related]
15. Glucose-induced insulin secretion is potentiated by a new imidazoline compound. Mest HJ; Raap A; Schloos J; Treinies I; Paal M; Giese U; Koivisto V Naunyn Schmiedebergs Arch Pharmacol; 2001 Jul; 364(1):47-52. PubMed ID: 11485038 [TBL] [Abstract][Full Text] [Related]
16. Comparison of insulin secretory patterns in obese nondiabetic LA/N-cp and obese diabetic SHR/N-cp rats. Role of hyperglycemia. Recant L; Voyles NR; Timmers KI; Bhathena SJ; Solomon D; Wilkins S; Michaelis OE Diabetes; 1989 Jun; 38(6):691-7. PubMed ID: 2656338 [TBL] [Abstract][Full Text] [Related]
17. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes. Irwin N; Pathak V; Pathak NM; Gault VA; Flatt PR Diabetes Obes Metab; 2015 Sep; 17(9):887-95. PubMed ID: 26095087 [TBL] [Abstract][Full Text] [Related]
18. Quantitative measurement of islet glucagon response to hypoglycemia by confocal fluorescence imaging in diabetic rats: effects of phlorizin treatment. Rastogi KS; Cooper RL; Shi ZQ; Vranic M Endocrine; 1997 Dec; 7(3):367-75. PubMed ID: 9657075 [TBL] [Abstract][Full Text] [Related]